Most Accessed Article – Regulatory Role of Heat Shock Proteins in the Pathogenesis of Type 1 and Type 2 Diabetes – Current Immunology Reviews

Journal: Current Immunology Reviews

Author(s): Christiane Habich, Henrike Sell, Volker Burkart

Graphical Abstract:

Abstract:

Diabetes is a severe metabolic disorder characterized by hyperglycemia due to defects in insulin secretion and/or insulin action. Over the past decades, a continuous rise of the incidence of diabetes is observed, leading to epidemic dimensions of the disease in large parts of the western world. Depending on the type of diabetes, (auto-)immune processes (type 1 diabetes) or metabolic disorders (type 2 diabetes) dominate the pathogenesis of the disease. Therefore, investigations aiming at the identification of disease mechanisms and the development of preventive and therapeutic approaches, focus on the identification of common regulators of both immunologic and metabolic pathways involved in the pathogenesis of diabetes. So far, extensive research, employing clinical and experimental approaches demonstrate a central role of heat shock proteins (HSPs) in diabetes development. In type 1 diabetes intracellular HSPs located in the beta cell can provide efficient protection against the deleterious effects of autoimmune effector mechanisms whereas extracellular HSPs can stimulate the release of beta cell damaging mediators from innate immune cells or even contribute to the induction of immune reactivity against beta cell specific antigens. In type 2 diabetes HSPs are involved in the control of various immunologic and metabolic processes contributing to the induction and maintenance of low-grade, subclinical inflammation associated with the development of diabetes and related disorders such obesity and insulin resistance. The results of current research on the pathogenesis of diabetes point to HSPs and HSP-dependent immunologic and metabolic pathways as promising targets for strategies to prevent or cure diabetes and its sequelae.

 

To access the article, please visit: http://www.eurekaselect.com/152952

 

 

Highlighted Article – Il-27: Friend or Foe in the Autoimmune Diseases – Current Immunology Reviews

CIR- Ali Ganji

http://benthamscience.com/journals/current-immunology-reviews/author-comments/

Wishing A Very Happy Birthday to Dr. Cecil Czerkinsky!

Dr. Cecil Czerkinsky

Dr. Cecil Czerkinsky

EDITOR-IN-CHIEF: Current Immunology Reviews

Institut de Pharmacologie Moleculaire et Cellulaire
UMR 7275 CNRS-INSERM-UNISA
660 Route des Lucioles
Valbonne, 06560
France

Most Accessed Article – Inflammasomes – A Mini-Review – Current Immunology Reviews

Journal: Current Immunology Reviews

Author(s): Mahirah Mahmud, Mek K. Jing, Adi Idris.

Abstract:

The cells of the innate immune system continually undergo surveillance of the extracellular milieu to serve as the first line of defense against invading microbial pathogens. As a result, these innate immune cells have evolved receptors to sense microbial motifs and danger signals. The inflammasome is an important component of the innate immune system’s “arsenal” against invading microbes such as viruses and bacteria and acts as a homeostatic checkpoint to regulate inflammation. Inflammasomes are cytosolic multi-protein complexes that activate caspase 1 and 11, which result in the production of pro-inflammatory interleukin (IL)-1β and IL-18, and cell death. Several studies have uncovered the mechanisms of inflammasome activation in response to various stimuli ranging from environmental stimulants to microbial components. This mini-review summarizes the current developments and updates in the mechanism of action of inflammasomes.

To access the article, please visit: http://www.eurekaselect.com/132833

SMi EVENT – 4th annual Immunogenicity

SMi is thrilled to present the return of its 4th annual Immunogenicity conference and exhibition, taking place in London on the 12th – 13th June 2017.

immuno

The immunogenicity market has seen considerable progression over recent years, with innovative developments apparent in predicting and controlling immunogenicity. However the industry is still subject to complex hurdles and challenges.

This year’s conference will provide attendees with a thorough understanding of the continued need for harmonisation across risk assessments and data reporting, as well as guidance for clinical trial design. Speakers will offer deep exploration of the regulations surrounding immunogenicity testing, from the UK, Europe, and USA, giving exclusive opportunity for discussion and debate with key regulatory experts. With focus on delivering true value for all delegates in attendance, Immunogenicity 2017 will identify and solve key challenges for industry experts. Insight into aggregations, next generation biologics, novel assays, humanisation of bio-therapeutics, and improvements to accurate risk assessment will be complemented by high level case studies.

At SMi’s 4th annual Immunogenicity conference, industry, regulatory and academic experts will gather to spark debate and progress on the causes of immunogenicity, predicting and preventing its effects, and its associated issues. Immunogenicity 2017 will offer unparalleled networking opportunities, deep insight into industry issues, and spotlight sessions on innovations and emerging technologies for immunogenicity.

Visit the website for further details at www.immuno.co.uk/bentham or contact at kwilliams@smi-online.co.uk

Journal: Current Immunology Reviews 

EBook: The Inflammatory Milieu of Tumors: Cytokines and Chemokines that Affect Tumor Growth and Metastasis 

Measles Immunisation Day – 16th March 2017!

measles-immunisation-day-bentham-science

Measles is a highly contagious viral disease which affects mostly children. It is one of the leading causes of death and disability among young children. Measles Immunisation Day is celebrated on 16th march every year to make people aware about this deadly disease and how they can deal with the same.
Bentham Science publishes research papers that present new studies related to to this particular disease. Find the latest studies in the following journal:

World Leprosy Eradication Day!

leprosy-eradication-day-bentham-science

Leprosy, also known as Hansen’s disease (HD), is a long-term infection by the bacteria Mycobacterium leprae. Symptoms of leprosy include granulomas of the nerves, respiratory tract, skin, and eyes, which result in lack of ability to feel pain.
Bentham Science publishes research papers that present new studies to help eradicate Leprosy. Find the latest studies in the following journals:

Immunology‚ Endocrine & Metabolic Agents in Medicinal ChemistryInfectious Disorders – Drug TargetsCurrent Immunology Reviews

Testimonial by Dr. Konstantin V. Suslov!

Dr. Konstantin V. Suslov

Dr. Konstantin V. Suslov

Institute of Immunology, 24/2 Kashirskoe Sh.,

Moscow 115 478, Russia

Contributed Article: Orchestrating HIV Neutralization by Secondary Immune Response- Mediated Induction of RF Antibodies

Upcoming Thematic Issue – Heat Shock Proteins in Health and Disease

Hottopic- Cir- Jurgen Radons

http://benthamscience.com/journals/current-immunology-reviews/

E-Pub Ahead of Print :: “Developments Towards a Prophylactic Hepatitis C Virus Vaccine”

Journal: Current Immunology Reviews

Author(s): Brian P. Latimer, Ebony Gary and Michele A Kutzler

cirAbstract: Chronic hepatitis C virus (HCV) infection is a major health problem worldwide, affecting approximately 3% of the human population. Although decades of research have amassed since the virus was characterized in 1989, there remains no prophylactic HCV vaccine approved for clinical use. The vast genetic variability of HCV, together with weak host immune responses following infection, and a paucity of suitable animal models for HCV vaccine research, have made HCV an elusive vaccine target. Despite the recent advances in medical treatment enjoyed by wealthy nations, there remains an unmet need for an affordable, effective, and accessible means to control HCV disease burden in areas of limited resources, where HCV is most problematic. To this end, several promising HCV vaccine candidates have been reported in recent preclinical and clinical trials. Here we review HCV virology and immunology relevant to rational design of a prophylactic HCV vaccine, and recent studies of preclinical and clinical HCV vaccine candidates.

For more details: http://benthamscience.com/journals/current-immunology-reviews/article/141596/